FIELD: medicine.
SUBSTANCE: group of inventions concerns treating breast cancer. Disclosed are: use of eribulin or salt thereof for treating HER2-negative breast cancer in a patient previously untreated; method for detecting a candidate patient for treatment of erybulin or a salt thereof of HER2-negative breast cancer; method of selecting such a patient; in vitro method of assessing the suitability of an individual for treating erubuline or a salt thereof; use of the method in vitro to assess the status of HER2 in a sample of a patient suffering breast cancer, and a method of treating HER2-negative breast cancer.
EFFECT: technical result consists in the effectiveness of treating the erybulin of both HER2- and three-fold negative breast cancer, including metastatic (advanced) cancer, in increasing the overall survival of the patients compared to capecitabine in the acceptable profile of the safety of the eribulin in such patients.
18 cl, 13 dwg, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| METHOD FOR TREATING THRICE-NEGATIVE BREAST CANCER | 2017 |
|
RU2757905C2 |
| METHOD FOR TREATMENT OF ANDROGEN RECEPTOR (AR)-POSITIVE FORMS OF BREAST CANCER USING SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM) | 2013 |
|
RU2648959C2 |
| METHOD OF TREATING ANDROGEN RECEPTOR (AR)-POSITIVE FORMS OF BREAST CANCER USING SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM) | 2013 |
|
RU2717835C2 |
| METHOD FOR DETERMINING THERAPEUTIC APPROACH IN PATIENTS WITH METASTATIC FORMS AND RECURRENT TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2818730C1 |
| METHOD OF TREATING BREAST CANCER WITH COMPOUND OF 4-IODINE-3-NITROBENZAMINE IN COMBINATION WITH ANTICANCER AGENTS | 2008 |
|
RU2480211C2 |
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER | 2016 |
|
RU2737216C2 |
| USE OF PARP INHIBITOR IN TREATMENT OF CHEMOTHERAPY-RESISTANT OVARIAN CANCER OR BREAST CANCER | 2018 |
|
RU2777519C2 |
| MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | 2013 |
|
RU2665949C2 |
